Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02371980 · ClinicalTrials.gov registry record · Phase 4
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
A Phase 4 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,106
- Enrollment target
NCT02371980 is a Phase 4 study that has completed, run by Takeda. The registered enrollment target is 1,106 participants.
The verdict
NCT02371980, a Phase 4 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD who responded to acute treatment with vortioxetine 10 mg.
Interventions
- DRUG Placebo
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,106 participants |
| Start Date | 2015-02-10 |
| Est. Completion | 2019-04-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02371980
The ClinicalTrials.gov registry entry for NCT02371980 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02371980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02371980 about?
NCT02371980 is a clinical study titled "Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)". The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD who responded to acute treatment with vortioxetine 10 mg.
What is the current status of trial NCT02371980?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,106 participants. The study started on 2015-02-10. Estimated completion is 2019-04-25.
What interventions are being tested in trial NCT02371980?
The interventions under investigation include: Placebo (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02371980?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.